RxDoctor Payments Data

John Lazaro, MD

Internal Medicine · West Columbia, SCNPI 1649238684

Payments from drug & device makers

$3,082in general payments, 2019–2025

Across 145 payments — averaging $21.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$431
  • Novo Nordisk$401
  • Dexcom, Inc.$356
  • Lilly USA, LLC$272
  • Novartis$214
  • Pfizer$163
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,082100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,082 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$142,868
Medicare patients
334
Services billed
2,778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate56$69,137
JardianceEmpagliflozin71$66,467
EliquisApixaban68$46,616
OzempicSemaglutide25$35,529
XifaxanRifaximin11$33,682
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$30,141
FarxigaDapagliflozin Propanediol30$20,121
MounjaroTirzepatide16$16,181
Tresiba Flextouch U-200Insulin Degludec19$12,956
Lantus SolostarInsulin Glargine,hum.Rec.Anlog70$10,203
TrulicityDulaglutide12$9,733
XareltoRivaroxaban11$6,855
LinzessLinaclotide13$6,728
Rosuvastatin Calcium208$4,257
Atorvastatin Calcium335$3,992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$61$69,13756 claims
Boehringer IngelheimJardiance$40$66,46771 claims
PfizerEliquis$163$46,61668 claims
Novo NordiskOzempic$401$35,52925 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$113$33,68211 claims
Lilly USA, LLCMounjaro, Trulicity$272$25,91428 claims
AstraZenecaFarxiga$431$20,12130 claims
AbbVieLinzess, Synthroid$113$9,99850 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →